arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Mosaic ImmunoEngineering Inc.

CPMV
— Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Neutral
auto_awesome

Analytical Summary

Mosaic ImmunoEngineering Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 2.0% →
FCF / Share $-0.00 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-177.50K
↓ -3.2% —
FCF / Share Free cash flow per share
$-0.00
↑ +98.7% —

Health Breakdown

Returns ↓
65
Financial Health ↑
16
Cash Quality ↓
28

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 67 quarters